Dr. Mary L. Gavin, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 3855 West Chester Pike, Suite 280, Nemours Dupont Pediatrics, Newton Square, Newton Square, PA 19073 Phone: 610-557-4800 Fax: 302-651-4945 |
News Archive
The role of sex in human disease is a growing area of research. Although estrogen (in females) and androgens (in males) are often seen as possible causes for such differences, sex chromosomes, including the male-specific Y chromosome, may also play a role. However, it has been difficult to understand how the Y chromosome could contribute to disease in men, in part because it is much more difficult to sequence than all other chromosomes.
Liquidia Technologies, a privately held nanotechnology company developing particle-based vaccines and therapeutics, today announced the initiation of human dosing of its lead vaccine product candidate, LIQ-001, in a Phase 1 clinical trial. LIQ-001, the first in a pipeline of PRINT® vaccines, is being developed as a seasonal influenza vaccine for enhanced protection in the elderly and represents the company's migration from proof of concept to the clinical application of PRINT technology.
Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today reported positive interim results from a preclinical trial for an H7N9 Avian Influenza VLP vaccine candidate ("H7 vaccine").
Chelsea Therapeutics International, Ltd. has initiated enrollment in a multinational, 12-week, double-blind Phase II trial designed to compare the efficacy and tolerability of CH-4051 against methotrexate (MTX) in 250 patients with rheumatoid arthritis (RA) who are experiencing an inadequate response to MTX treatment.
Fewer people would die of colorectal cancer if health care providers adopted a new model of screening that combines better risk assessment, more options for noninvasive testing and more targeted referrals for colonoscopy.
› Verified 9 days ago